XML 46 R35.htm IDEA: XBRL DOCUMENT
v3.23.2

REVENUES - Summary of Disaggregation of Revenues (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | $ 6,599 | $ 6,260 | $ 12,951 | $ 12,850
U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 4,784 | 4,339 | 9,236 | 8,694
Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 1,027 | 1,076 | 2,106 | 2,277
Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 789 | 844 | 1,610 | 1,878
Total product sales |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 6,564 | 6,138 | 12,870 | 12,672
Total product sales | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 4,777 | 4,254 | 9,211 | 8,582
Total product sales | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 999 | 1,042 | 2,052 | 2,216
Total product sales | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 788 | 842 | 1,607 | 1,873
Total HIV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 4,626 | 4,228 | 8,816 | 7,935
Total HIV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3,778 | 3,383 | 7,142 | 6,245
Total HIV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 521 | 562 | 1,049 | 1,112
Total HIV | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 326 | 282 | 624 | 577
Biktarvy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 2,979 | 2,556 | 5,656 | 4,707
Biktarvy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 2,439 | 2,095 | 4,600 | 3,801
Biktarvy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 302 | 268 | 606 | 529
Biktarvy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 237 | 193 | 449 | 376
Complera/Eviplera |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 32 | 54 | 70 | 99
Complera/Eviplera | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 13 | 20 | 27 | 37
Complera/Eviplera | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 16 | 31 | 37 | 55
Complera/Eviplera | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3 | 3 | 6 | 7
Descovy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 516 | 460 | 965 | 834
Descovy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 460 | 397 | 855 | 708
Descovy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 25 | 32 | 50 | 64
Descovy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 31 | 32 | 60 | 63
Genvoya |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 540 | 582 | 1,041 | 1,164
Genvoya | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 455 | 482 | 872 | 939
Genvoya | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 56 | 72 | 111 | 149
Genvoya | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 29 | 29 | 58 | 76
Odefsey |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 351 | 364 | 668 | 703
Odefsey | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 267 | 255 | 497 | 487
Odefsey | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 74 | 97 | 149 | 193
Odefsey | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 11 | 12 | 22 | 23
Stribild |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 26 | 33 | 55 | 66
Stribild | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 19 | 24 | 39 | 46
Stribild | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 5 | 8 | 11 | 16
Stribild | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 2 | 2 | 4 | 5
Truvada |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 42 | 34 | 74 | 72
Truvada | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 32 | 24 | 55 | 52
Truvada | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3 | 5 | 7 | 9
Truvada | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 7 | 5 | 12 | 11
Revenue share - Symtuza |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 120 | 126 | 259 | 258
Revenue share - Symtuza | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 84 | 80 | 182 | 166
Revenue share - Symtuza | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 33 | 42 | 70 | 86
Revenue share - Symtuza | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3 | 4 | 7 | 6
Other HIV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 20 | 18 | 29 | 33
Other HIV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 10 | 5 | 15 | 10
Other HIV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 7 | 9 | 8 | 13
Other HIV | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3 | 4 | 6 | 9
Total Oncology |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 728 | 527 | 1,398 | 947
Total Oncology | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 462 | 366 | 893 | 658
Total Oncology | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 215 | 141 | 417 | 258
Total Oncology | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 51 | 21 | 88 | 32
Total Cell Therapy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 469 | 368 | 916 | 642
Total Cell Therapy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 272 | 246 | 542 | 418
Total Cell Therapy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 162 | 105 | 310 | 197
Total Cell Therapy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 34 | 17 | 65 | 27
Tecartus |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 88 | 73 | 177 | 136
Tecartus | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 56 | 53 | 114 | 100
Tecartus | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 29 | 20 | 56 | 35
Tecartus | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 4 | 0 | 6 | 1
Yescarta |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 380 | 295 | 739 | 506
Yescarta | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 217 | 193 | 427 | 318
Yescarta | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 133 | 85 | 254 | 162
Yescarta | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 30 | 17 | 58 | 26
Trodelvy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 260 | 159 | 482 | 305
Trodelvy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 189 | 120 | 351 | 240
Trodelvy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 53 | 35 | 107 | 61
Trodelvy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 17 | 3 | 23 | 5
Total Liver Disease |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 711 | 682 | 1,386 | 1,317
Total Liver Disease | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 356 | 363 | 674 | 642
Total Liver Disease | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 131 | 124 | 271 | 247
Total Liver Disease | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 225 | 195 | 441 | 427
Total HCV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 452 | 448 | 897 | 847
Total HCV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 259 | 263 | 491 | 462
Total HCV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 95 | 94 | 209 | 189
Total HCV | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 98 | 91 | 197 | 196
Ledipasvir/Sofosbuvir |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 15 | 23 | 30 | 58
Ledipasvir/Sofosbuvir | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 8 | 6 | 12 | 19
Ledipasvir/Sofosbuvir | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 2 | 4 | 9 | 8
Ledipasvir/Sofosbuvir | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 5 | 13 | 10 | 31
Sofosbuvir/Velpatasvir |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 397 | 376 | 782 | 706
Sofosbuvir/Velpatasvir | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 223 | 227 | 427 | 389
Sofosbuvir/Velpatasvir | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 84 | 75 | 174 | 157
Sofosbuvir/Velpatasvir | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 90 | 74 | 181 | 159
Other HCV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 40 | 49 | 85 | 83
Other HCV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 28 | 30 | 51 | 54
Other HCV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 9 | 16 | 27 | 24
Other HCV | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3 | 3 | 6 | 5
Total HBV/HDV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 259 | 234 | 489 | 470
Total HBV/HDV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 97 | 100 | 183 | 180
Total HBV/HDV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 35 | 30 | 62 | 57
Total HBV/HDV | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 127 | 104 | 244 | 232
Vemlidy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 219 | 195 | 418 | 394
Vemlidy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 96 | 97 | 183 | 177
Vemlidy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 10 | 9 | 19 | 18
Vemlidy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 113 | 89 | 216 | 199
Viread |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 21 | 24 | 40 | 47
Viread | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 1 | 3 | 1 | 3
Viread | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 6 | 6 | 12 | 12
Viread | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 14 | 15 | 28 | 32
Other HBV/HBD |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 20 | 16 | 31 | 28
Other HBV/HBD | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 0 | 0 | 0 | 0
Other HBV/HBD | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 20 | 15 | 31 | 28
Other HBV/HBD | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 0 | 0 | 0 | 0
Veklury |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 256 | 445 | 829 | 1,980
Veklury | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 97 | 41 | 349 | 843
Veklury | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 52 | 126 | 163 | 430
Veklury | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 107 | 278 | 317 | 708
Total Other |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 243 | 256 | 442 | 493
Total Other | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 85 | 101 | 153 | 195
Total Other | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 80 | 88 | 152 | 169
Total Other | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 78 | 67 | 137 | 129
AmBisome |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 151 | 132 | 267 | 275
AmBisome | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 20 | 15 | 27 | 40
AmBisome | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 69 | 63 | 129 | 129
AmBisome | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 61 | 54 | 111 | 107
Letairis |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 39 | 49 | 70 | 92
Letairis | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 39 | 49 | 70 | 92
Letairis | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 0 | 0 | 0 | 0
Letairis | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 0 | 0 | 0 | 0
Other |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 53 | 76 | 105 | 125
Other | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 26 | 37 | 56 | 63
Other | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 10 | 26 | 22 | 41
Other | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 17 | 13 | 26 | 22
Royalty, contract and other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 35 | 122 | 81 | 178
Royalty, contract and other revenues | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 6 | 85 | 25 | 112
Royalty, contract and other revenues | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 28 | 34 | 54 | 61
Royalty, contract and other revenues | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | $ 1 | $ 2 | $ 3 | $ 5

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=gild_OtherInternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsStribildMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OncologyProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_TrodelvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_LiverDiseaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherHepatitisCVirusProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_VekluryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |